The Protein Sequencing industry trends over the past 12‑18 months reflect accelerating commercialization and strategic consolidation. In Q2 2024, Thermo Fisher Scientific entered a multi‑year partnership with Illumina to co‑develop high‑throughput nanopore‑based sequencers, expanding assay compatibility for clinical proteomics. Meanwhile, Pacific Biosciences completed its acquisition of biotech start‑up ScribeBio, adding single‑molecule peptide‑reading technology to its portfolio. New product launches include Oxford Nanopore’s Proteome‑X platform, which promises real‑time, label‑free protein identification with sub‑nanogram sensitivity, and Bruker’s MALDI‑FTICR upgrade that integrates AI‑driven deconvolution. Regulatory momentum grew as the FDA released revised guidance on “Protein Biomarker Qualification” in September 2023, shortening approval timelines for diagnostic assays. Enterprise demand shifted toward cloud‑native analytics, prompting several vendors to embed SaaS pipelines. Finally, venture capital activity surged, highlighted by a $120 million Series C round for DeepSeq, earmarked for scaling its proprietary mass‑spectrometry workflow across Europe. In parallel, GenScript opened a new R&D hub in Singapore to serve APAC customers, leveraging its recent $45 million Series B funding to accelerate assay development.
